In the article on topotecan combination chemotherapy in retinoblastoma published in the October 15, 2005 issue of Clinical Cancer Research, the data for Fig. 3B were incorrectly represented. In this figure, the authors presented plasma and vitreous carboplatin concentration-time data. The range of values on the y axis in Fig. 3B was incorrectly represented as from 0.1 to 1 μM, but should have been from 1 to 1000 μM. The published figure underestimated the actual carboplatin exposure in plasma and vitreous of rats. The corrected figure shoes that carboplatin vitreal concentrations after a 70 mg/kg intravenous dosage are potentially active as defined by the LC50 (4 μM) for the Y79 retinoblastoma cell line. The correct figure appears here.
Laurie NA, Gray JK, Zhang J, et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res 2005;11:7569–78.
RSS Feeds